Enveric Biosciences
ENVB | NASDAQ
$1.44
-$0.07 (-4.95%)
At close: Nov 16, 2026, 4:00 PM ET
$1.44
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-4.95%
(1D)No price chart data available for 1D timeframe.
Rating
19.8
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #994/1021 (Top 97%)
Key Statistics
Market Data
Market Cap $6.45M
1D Range
1.43 1.54
52W Range
1.27 10.33
Valuation (TTM)
PE -0.23
PB 1.13
EV/EBITDA -0.09
Valuation (NTM)
Forward PE N/A
Forward PEG -0.00
Price Target $0.00
Cash Flow
FCF Yield -141.8%
SBC Adj. FCF Yield -151.9%
SBC Impact -7.1%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y 65.0% |
77.8%
FCF 3Y | 5Y -5.8% |
22.7%
Returns
ROA -147.6%
ROE -163.2%
ROIC -164.5%
Financial Health
Net Cash
$5.61M
Current Ratio 9.70
Interest Coverage -8,477.61
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, d...
Sector Healthcare
Industry Biotechnology
Employees 6
IPO Date May 4, 2015
Website www.enveric.com
Fiscal Year January - December
Latest News
No news articles available yet.
Add to Watchlist
Select watchlists to add or remove ENVB